Market Overview

Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target

Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target
Related XLRN
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes.

The candidate also posted  positive results in a late-stage trial that evaluated it for transfusion-dependent beta thalassemia.

The Analyst

The rally sent Morgan Stanley analyst Matthew Harrison to the sidelines. He downgraded Acceleron from Overweight to Equal-weight and maintained a $50 price target. 

The Thesis

Acceleron's luspatercept data is strong, positioning the company for a filing in the first half of 2019, but there is possibility of limited near-term upside, Harrison said in a Friday morning note. (See the analyst's track record here.) 

Harrison's view that the novel TGF-beta platform is a better way to treat anemia has largely materialized following the positive data reported for the two indications, he said. The analyst projects limited upside until more details are presented on the magnitude of the efficacy response and safety, which is likely to come at the December American Society of Hematology meeting. 

"Other catalysts include initial data on ACE-083,including the final dose-escalation results in [the second half of 2018] as well as initial ACE2494 data in [the first half of 2019." 

With both Phase 3 readouts now reflected in Acceleron's valuation, Harrison said the stock has a more balanced risk-reward profile. 

Key upside drivers include luspatercept data, which could notably increase sales estimates, or data from the early stage pipeline, which is not reflected in Acceleron's valuation, the analyst said. 

The Price Action

Acceleron shares have added about 11 percent year-to-date.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Latest Ratings for XLRN

Sep 2018PiperJaffrayUpgradesNeutralOverweight
Sep 2018Morgan StanleyAssumesEqual-Weight
Jul 2018Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for XLRN
View the Latest Analyst Ratings

Posted-In: Matthew Harrison Morgan StanleyAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (XLRN)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Cannabis After Legalization: Vic Neufeld Shares Aphria's Plan For Growth

Getting Started With Retirement Planning? Here Are A Few Steps